Back to top
more

Viemed Healthcare (VMD)

(Delayed Data from NSDQ)

$8.85 USD

8.85
202,602

-0.21 (-2.32%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $8.84 -0.01 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 48% (130 out of 250)

Industry: Medical - Products

Zacks News

Can Viemed Healthcare, Inc. (VMD) Climb 112% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at an 111.9% upside potential for Viemed Healthcare, Inc. (VMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Viemed Healthcare, Inc. (VMD) Lags Q3 Earnings Estimates

Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of -20.00% and 5.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Viemed Healthcare, Inc. (VMD) to Report a Decline in Earnings: What to Look Out for

Viemed Healthcare, Inc. (VMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viemed Healthcare, Inc. (VMD) Surpasses Q2 Earnings Estimates

Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of 100.00% and -0.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Viemed Healthcare, Inc. (VMD) Q2 Earnings Expected to Decline

Viemed Healthcare, Inc. (VMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viemed Healthcare, Inc. (VMD) Q1 Earnings Top Estimates

Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of 33.33% and -2.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?